RxDoctor Payments Data

Michael Shahla, MD

Internal Medicine · Naples, FLNPI 1548480270

Payments from drug & device makers

$116in general payments, 2019–2025

Across 8 payments — averaging $14.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$29
  • AstraZeneca$24
  • Amgen$15
  • Sanofi Pasteur Inc.$13
  • AbbVie$12
  • Portola Pharmaceuticals, LLC$12
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$116100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$116 in reported general payments places this provider in the 30th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$564,764
Medicare patients
823
Services billed
9,516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$177,574
OzempicSemaglutide98$138,830
Bydureon BciseExenatide Microspheres18$41,144
XareltoRivaroxaban30$36,279
Repatha SureclickEvolocumab27$34,540
JardianceEmpagliflozin14$24,601
Breo ElliptaFluticasone/Vilanterol29$23,834
MyrbetriqMirabegron27$22,970
MounjaroTirzepatide14$22,644
JanuviaSitagliptin Phosphate21$21,787
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$16,248
SynthroidLevothyroxine Sodium119$11,997
VascepaIcosapent Ethyl20$9,420
Rosuvastatin Calcium503$6,532
Atorvastatin Calcium547$5,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$11$138,83098 claims
AbbVieSynthroid$12$11,997119 claims
AstraZenecaBevespi Aerosphere$24$4,60011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →